Grace Therapeutics, IncNASDAQ:GRCE
- LAST PRICE3.2800
- TODAY'S CHANGE (%)0.0500 (1.5480%)
- Bid / Lots3.0500/ 1
- Ask / Lots3.4500/ 40
- Open / Previous Close3.1800 / 3.2300
- Day Range
- 52 Week Range
- Volume36,020
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRCE |
|---|---|---|
| 09:32 ET | 494 | 3.18 |
| 10:26 ET | 100 | 3.18 |
| 10:49 ET | 2000 | 3.07 |
| 11:34 ET | 300 | 3.33 |
| 12:24 ET | 1100 | 3.29 |
| 12:26 ET | 5978 | 3.38 |
| 12:28 ET | 251 | 3.38 |
| 12:30 ET | 2000 | 3.34 |
| 12:39 ET | 1400 | 3.28 |
| 12:42 ET | 309 | 3.28 |
| 12:44 ET | 500 | 3.27 |
| 01:02 ET | 221 | 3.27 |
| 01:20 ET | 200 | 3.31 |
| 01:31 ET | 102 | 3.31 |
| 01:38 ET | 100 | 3.31 |
| 01:47 ET | 125 | 3.312 |
| 01:49 ET | 5710 | 3.29 |
| 01:51 ET | 5626 | 3.28 |
| 02:07 ET | 102 | 3.28 |
| 02:18 ET | 103 | 3.28 |
| 02:27 ET | 107 | 3.28 |
| 02:36 ET | 107 | 3.28 |
| 02:43 ET | 107 | 3.28 |
| 02:48 ET | 100 | 3.3 |
| 02:54 ET | 1000 | 3.275 |
| 02:59 ET | 100 | 3.275 |
| 03:01 ET | 2209 | 3.28 |
| 03:03 ET | 113 | 3.28 |
| 03:10 ET | 107 | 3.28 |
| 03:17 ET | 104 | 3.28 |
| 03:24 ET | 103 | 3.28 |
| 03:28 ET | 104 | 3.264 |
| 04:00 ET | 100 | 3.28 |
Nov 13, 2024
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 30, 2024
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024, from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 28, 2024
*DJ News On Acasti Pharma Inc. (ACST) Now Under GRCE, from 5:08PM ET on Monday Oct 28, 2024 by Dow Jones
5:08PM ET on Monday Oct 28, 2024 by Dow Jones
Oct 25, 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc., from 8:00AM ET on Friday Oct 25, 2024 by Dow Jones
8:00AM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Grace Therapeutics, Inc | 32.8M | -3.0x | --- |
LianBio | 32.4M | -0.4x | --- |
Passage Bio Inc | 33.1M | -0.4x | --- |
Estrella Immunopharma Inc | 32.2M | -3.8x | --- |
Citius Pharmaceuticals Inc | 31.9M | -0.5x | --- |
Lantern Pharma Inc | 31.8M | -1.7x | --- |
Company Information
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
Contact Information
- Headquarters
- 103 Carnegie Center, Suite 300PRINCETON, NJ, United States 08540
- Phone
- 609-322-1602
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Vimal Kavuru
- Chief Executive Officer
- Prashant Kohli
- Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
- Robert Delaversano
- Vice President - Clinical Operations
- Carrie D'Andrea
- Vice President - Program Management
- Amresh Kumar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.50 |
EPS | $-1.08 |
Book Value | $6.57 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
